featured
Nintedanib Plus mFOLFOX6 as First-Line Therapy for Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase I/II, Open-Label, Randomized Study of Nintedanib Plus mFOLFOX6 Versus Bevacizumab Plus mFOLFOX6 in First-Line Metastatic Colorectal Cancer Patients
Ann. Oncol 2015 Aug 12;[EPub Ahead of Print], E Van Cutsem, H Prenen, G D'Haens, J Bennouna, A Carrato, M Ducreux, O Bouché, A Sobrero, L Latini, H Staines, Z Oum'Hamed, H Dressler, M Studeny, J CapdevilaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.